Dendritic cell-based vaccines for the therapy of experimental tumors

Immunotherapy

Volumn 2, Issue 2, 2010, Pages 257-268

  Pajtasz Piasecka, Elzbieta ^a   Indrová, Marie ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Dendritic cell; Experimental tumor; Preparation of vaccine

Indexed keywords

ADENOVIRUS VECTOR; ANTIGEN; AXCAGP70 VACCINE; BM DC T4 VACCINE; BM DC VACCINE; CD40 LIGAND MONOCLONAL ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DC2.4 VACCINE; DENDRITIC CELL VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; JAWS II VACCINE; RECOMBINANT FRACTALKINE; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 18; RECOMBINANT PROTEIN; TAG VACCINE; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; TUMOR VACCINE; UNCLASSIFIED DRUG; UNLOADED DC VACCINE; CANCER VACCINE; TUMOR ANTIGEN;

CANCER IMMUNIZATION; CANCER THERAPY; CELL DIFFERENTIATION; CELL MATURATION; CELL TRANSFER; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLON CARCINOMA; DENDRITIC CELL; DNA MODIFICATION; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; EX VIVO STUDY; EXPERIMENTAL NEOPLASM; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG CARCINOMA; MELANOMA; NEOPLASM; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; TISSUE; TREATMENT INDICATION; TUMOR CELL; TUMOR IMMUNITY; ACTIVE IMMUNIZATION; ANIMAL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; CELL CULTURE; CYTOLOGY; DRUG SCREENING; FORECASTING; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; INBRED MOUSE STRAIN; INTRADERMAL DRUG ADMINISTRATION; INTRALYMPHATIC DRUG ADMINISTRATION; MOUSE; MULTIMODALITY CANCER THERAPY; NEOPLASMS, EXPERIMENTAL; SUBCUTANEOUS DRUG ADMINISTRATION; THERAPEUTIC USE; TRANSPLANTATION; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL DIFFERENTIATION; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYTOKINES; DENDRITIC CELLS; DRUG SCREENING ASSAYS, ANTITUMOR; FORECASTING; GENETIC THERAPY; GENETIC VECTORS; IMMUNOTHERAPY, ACTIVE; INJECTIONS, INTRADERMAL; INJECTIONS, INTRALYMPHATIC; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; ORGAN SPECIFICITY; VACCINATION;

EID: 77953434447     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.7     Document Type: Review

References (103)

1. Gilboa E: DC-based cancer vaccines. J. Clin. Invest. 117, 1195-1203 (2007).
2. Nencioni A, Grunebach F, Schmidt S et al.: The use of dendritic cells in cancer immunotherapy Crit. Rev. Oncol. Hematol. 65, 191-199 (2008).
3. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM: Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol. Immunother. 58, 1-14 (2009).
4. Nestle FO, Farkas A, Conrad C: Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol.17, 163-169 (2005).
5. Tuyaerts S, Aerts J, Corthals J et al.: Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother. 56, 1513-1537 (2007).
6. Koski G, Cohen P, Roses R et al.: Reengineering dendritic cell-based anti-cancer vaccines Immunol. Rev. 222, 256-276 (2008).
7. Wu L, Liu YJ: Development of dendritic-cell lineages. Immunity 26, 741-750 (2007).
8. Ueno H, Klechevsky E, Morita R et al.: Dendritic cell subsets in health and disease. Immunol. Rev. 219, 118-142 (2007).
9. Jacobs N, Boniver J, Hubert P, Delvenne PH: Dendritic cells: more than just adaptive immunity inducers? Curr. Immunol.Rev. 3, 17-22 (2007).
10. Wang Y, Liu Y: Mysterious origin of plasmacytoid dendritic cell precursors. Immunity. 21, 1-5 (2004).
11. Steimann R: Dendritic cells in vivo: a key target for a new vaccine science. Immunity 29(3), 319-324 (2008).
12. + T cell activation in vivo. J. Immunol. 181, 3811-3817 (2008).
13. Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A: Immunotherapy with dendritic cells for cancer. Adv. Drug Deliv. Rev. 60, 173-183 (2008).
14. Aerts-Toegaert C, Heirman C, Tuyaerts S et al.: CD83 expression on dendritic cells and T cells: correlatin with effective immune responses. Eur. J. Immunol. 37, 686-695 (2007).
15. Prechtel AT, Turza NM, Theodoridis AA, Steinkasserer A: CD8 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation. J. Immunol. 178, 5454-5464 (2007).
16. Lopez-Bravo M, Ardavín C: In vivo induction of immune responses to pathogens by conventional dendritic cells. Immunity 29, 343-351 (2008).
17. Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger J. Leukoc. Biol. 81, 1-5 (2007).
18. Alvarez D, Vollmann EV, Anddian UH: Mechanisms and consequences of dendritic cell migration. Immunity 29, 325-342 (2008).
19. Steinman RM, Banchereau J: Taking dendritic cells into medicine. Nature 449, 419-1246 (2007).
20. Macagno A, Napolitani,G, Lanzavecchia A, Sallusto F: Duration, combination and timing: the signal integration model of dendritic cell activation. Trends Immunol. 28(5), 227-233 (2007).
21. Takeda K, Akira S: Toll-like receptors in innate immunity. Int. Immunol. 17, 1-14 (2005).
22. Weck MM, Grünebach F, Werth D et al.: hDectin-1 is involved in uptake and cross-presentation of cellular antigens. Blood 109, 3890-3894 (2007).
23. Breckpot K, Escors D: Dendritic cells for active anti/cancer immunotherapy: targeting activation pathways through genetic modifcations. Endocr. Metab. Immune Disord. Drug Targets DOI: 10.2174/187153009789839156 (2010) (Epub ahead of print).
24. + cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther. 13, 1027-1036 (2006).
25. Daubenberger CA: TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr. Opin. Mol. Ther. 9, 45-52 (2007).
26. Murad YM, Clay TM: CpG oligodeoxyneucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs 23, 361-375 (2009).
27. Tang CK, Pietersz GA: Intracellular detection and immune signaling pathways of DNA vaccines. Expert Rev. Vaccines 8, 1161-1170 (2009).
28. Apetoh L, Ghiringhelli F, Tesniere A et al.: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059 (2007).
29. Fujii S, Fakayama T, Asakura M, Aki K, Fujimoto K, Shimizu K: Dendritic cell-based immunotherapies. Arch. Immunol. Ther. Exp. 57, 189-198 (2009).
30. Chan CW, Housseau F: The 'kiss of death' by dendritic cells to cancer cells. Cell Death Differ. 15, 58-156 (2008).
31. Ardavín C, Amigorena S, Reise Sousa C: Dendritic cells: immunobiology and cancer immunotherapy. Immunity 20, 17-23 (2004).
32. Melief CJ: Cancer immunotherapy by dendritic cells. Immunity 29, 372-383 (2008).
33. Wen H, Schaller MA, Dou Y, Hogaboam CM, Kunkel SL: Dendritic cells at the interface of innate and acquired immunity: the role for epigenetic changes. J. Leukoc. Biol. 83, 439-446 (2008).
34. Bennaceur K, Chapman J, Brikci-Nigassa J, Sanhadji K, Touraine JL, Portoukalian J: Dendritic cells dysfunction in tumour environment. Cancer Lett. 272, 186-196 (2008).
35. Shurin MR, Gabrilovich DI: Regulation of dendritic cell system by tumor. Cancer Res. Ther. 11, 65-78 (2001).
36. Shurin MR, Shurin GV, Lokshin A et al.: Intratumoral cytokines/ chemokines/ growth factors and tumor infltrating dendritic cells: friends or enemies? Cancer Metastasis Rev. 25, 333-356 (2006).
37. Castellano G, Woltman AM, Nauta AJ et al.: Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood 103, 3813-3820 (2004).
38. Pirtskhalaishvili G, Shurin GV, Gambotto A et al.: Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J. Immunol. 165, 1956-1964 (2000).
39. Allavena P, MarchesiF, Mantovani A: The role of chemokines and their receptors in tumor progression and invasion: potential new targets of biological therapy. Curr. Cancer Ther. Rev. 1, 81-92 (2005).
40. Preynat-Seauve O, Schuler P, Contassot E, Beermann F, Huard B, French LE: Tumor-infltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J. Immunol. 176, 61-67 (2006).
41. Bennaceur K, Chapman JA, Touraine Jl, Portoukalian J: Immunosuppressive networks in the tumour environment and their effect in dendritic cells. Biochim. Biophys. Acta 1795, 16-24 (2009).
42. Sica A, Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117, 1155-1166 (2007).
43. Marigo I, Dolcetti L, Serafni P, Zanovello P, Bronte V: Tumor induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162-179 (2008).
44. 2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 97, 3466-3469 (2001).
45. Gabrilovich D: Mechanisms and functional signifcance of tumour induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941-952 (2004).
46. Inaba K, Inaba M, Romani N et al.: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 175, 1693-1702 (1992).
47. Lutz MB, Roessner S: Factors infuencing the generation of murine dendritic cells from bone marrow: the special role of fetal calf serum. Immunobiology 212, 855-862 (2008).
48. Shortman K, Caux C: Dendritic cell development: multiple pathways to nature's adjuvants. Stem Cells 15, 409-419 (1997).
49. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat. Med. 10, 475-478 (2004).
50. Rossowska J, Pajtasz-Piasecka E, Szyda A, Krawczenko A, Zietara N, Dus D: Tumour antigen-loaded mouse dendritic cells maturing in the presence of infammatory cytokines are potent activators of immune response in vitro but not in vivo. Oncol. Rep. 21, 1539-1549 (2009).
51. Balkow S, Loser K, Krummen M et al.: Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 effciently stimulates anti-tumor immunity. Exp. Dermatol. 18, 78-87 (2009)
52. Gong J, Chen I, Chen D et al: Inducion of antigen-specifc antitumor immunity with adenovirus/transduced dendritic cells. Gene Ther. 4 1023-1028 (1997).
53. Ribas A: Genetically modifed dendritic cells for cancer immunotherapy Curr. Gene Ther. 5, 619-628 (2005).
54. Chinnasamy N, Chinnasamy D, Toso JF et al.: Effcient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodefciency virus type 1-based lentiviral vectors. Hum. Gene Ther. 11, 1901-1909 (2000).
55. Tureci O, Bian H, Nestle FO et al.: Cascades of transcriptional induction during dendritic cell maturation revealed by genome-wide expression analysis. FASEB J. 17, 836-847 (2003).
56. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F: Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol. 1, 311-316 (2000).
57. Mendoza L, Bubeník J, Indrová M, Bieblová J, Vonka V, Šímová J: Freezing and thawing of murine bone marrow-derived dendritic cells does not alter their immunophenotype and antigen presentation characteristics. Folia Biol. (Praha) 48, 242-245 (2002).
58. de Vries IJ, Eggert AA, Scharenborg NM et al.: Phenotypical and functional characterization of clinical grade dendritic cells. J. Immunother. 25, 429-438 (2002).
59. Westermann J, Korner IJ, Kopp J et al.: Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: infuence on phenotype and functional properties. Cancer Immunol. Immunother. 52, 194-198 (2003).
60. Dietz AB, Padley DJ, Butler GW et al.: Clinical-grade manufacturing of DC from CD14 precursors: experience from Phase I clinical trials in CML and malignant melanoma. Cytotherapy 6, 563-570 (2004).
61. + monocytes. J. Immunother. 27, 27-35 (2004).
62. Mu LJ, Gaudernack G, Saeboe-Larssen S, Hammerstad HA: Tierens A, Kvalheim G: A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. Scand. J. Immunol. 58, 578-586 (2003)
63. Bubeník J: Genetically engineered dendritic cell-based cancer vaccines. Int. J. Oncol. 18, 475-478 (2001).
64. Šímová J, Bubeník J, Bieblová J, Indrová M, Jandlová T: Immunotherapeutic effcacy of vaccines generated by fusion of dendritic cells and HPV16-associated tumour cells. Folia Biol. (Praha) 5, 19-24 (2005).
65. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S: Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89, 2646-2654 (2000).
66. Rossowska J Pajtasz-Piasecka E, Szyda A, Zietara N, Dus D: Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their infuence on immune response Folia Histochem. Cytobiol. 45, 349-355 (2007).
67. Pajtasz-Piasecka E, Rossowska J, Dus D, Weber-Dabrowska B, Zabłocka A, Górski A: Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma. Immunol. Lett. 116, 24-32 (2008).
68. Indrová M, Reinis M, Bubeník J et al.: Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects. Folia Biol. (Praha) 50, 184-193 (2004).
69. Melief CJ, van der Burg SH: Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8, 351-360 (2008).
70. Reinis M, Stepánek I, Simová J et al.: Induction of protective immunity against MHC class I-defcient, HPV16-associated tumours with peptide and dendritic cell-based vaccines. Int. J. Oncol. 36, 545-551 (2010).
71. Wu A, Oh S, Gharagozlou S, Vedi RN et al.: In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J. Immunother. 30, 789-797 (2007).
72. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK: Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 59, 56-58 (1999).
73. Wu L, Engleman EG: Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166, 4254-4259 (2001).
74. + T-cell function in melanoma patients. J. Clin. Oncol. 21, 3826-3835 (2003).
75. Kyte JA, Gaudernack G: Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol. Immunother. 55, 1432-1442 (2006).
76. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ: Whole-cell cancer vaccination: from autologous to allogeneic tumor-and dendritic cell-based vaccines. 57(10), 1569-1577 (2008).
77. Singh S, Stephani J, Schaefer M et al.: Targeting glycan modifed OVA to murine DC-SING transgenic dendritic cells enhances MHC class I and II presentation. Mol. Immunol. 47, 164-174 (2009)
78. Kretz-Rommel A, Qin, F, Dakappagari N et al.: In vivo Targeting of antigens to human dendritic cells through DC-sign elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J. Immunother. 30, 715-726 (2007).
79. Breckpot K, Emeagi PU, Thielemans K: Lentiviral vaccines for ant/tumor targeting. Curr. Gene Ther. 8, 438-448 (2008).
80. Dullaer M, van Neirvenne S, Heirmn C et al.: Iduction of effective therapeutic antitumor immunity by direct in vivo administration of Lentiviral vectors. Gene Ther. 13, 630-640 (2006).
81. Jinushi M, Tahara1H: Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci. 100, 1389-1396 (2009).
82. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ: Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158, 3270-3276 (1997).
83. Wei H, Wang H, Lu B et al.: Cancer immunotherapy using in vitro genetically modifed targeted dendritic cells. Cell Res. 68, 3854-3862 (2008).
84. Nishioka Y, Hirao M, Robbins P et al.: Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modifed to express interleukin 12. Cancer Res. 59, 4035-4041 (1999).
85. Breckpot K, Heirman C, Neyns B, Thielemans K: Exploiting dendritic cells for cancer immunotherapy: genetic modifcation of dendritic cells. J. Gene Med. 6, 1175-1188 (2004).
86. Akiyama Y, Watanabe M, Maruyama K, Ruscetti FW, Wiltrout RH, Yamaguchi K: Enhancement of antitumor immunity against B16 melanoma tumor using genetically modifed dendritic cells to produce cytokines. Gene Ther. 24, 2113-2121(2000).
87. + cell-derived dendritic cells. Int. J. Oncol. 21, 509-514 (2002).
88. Ogawa F, Iinuma H, Okinaga K et al.: Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells. Scand. J. Immunol. 59, 432-439 (2004).
89. Ojima T, Iwahashi M, Nakamura M et al.: The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modifed dendritic cells expressing tumor-associated antigen. Int. J. Oncol. 28, 947-953 (2006).
90. Tatsumi T, Takehara T, Yamaguchi S et al.: Injection of IL-12-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Gene Ther. 14, 863-871 (2007).
91. Pajtasz-Piasecka E, Rossowska J, Szyda A, Krawczenko A, Dus D: Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes. Oncol. Rep. 17, 1249-1257 (2007).
92. Haynes NM, van der Most RG, Lake RA, Smyth MJ: Immunogenic anti-cancer chemotherapy as an emerging concept. Curr. Opin. Immunol. 20(5), 545-557 (2008).
93. He XZ, Wang L, Zhang YY et al.: An effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cells. Gastroenterol. 28, 532-540 (2008).
94. Nukiwa M, Andarini S, Zaini J et al.: Dendritic cells modifed to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Eur. J. Immunol. 36, 1019-1027 (2006).
95. Kim CH, Hong JM, Park SD et al.: Enhancement of anti-tumor immunity specifc to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12. Cancer Immunol. Immunother. 55, 1309-1319 (2006).
96. Mendoza L, Indrová M, Hájková R et al.: Peritumoral administration of antigen-unstimulated bone marrow-derived dendritic cells inhibits tumour growth. Folia Biol. (Praha) 46, 91-97(2000).
97. Indrová M, Bubeník J, Símová J et al.: Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide. Int. J. Mol. Med. 7, 97-100 (2001).
98. Mendoza L, Bubeník J, Símová J, Jandlová T, Vonka V, Mikysková R: Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int. J. Oncol. 23, 243-724 (2003).
99. Bubeník J, Mikysková R, Vonka V et al.: Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 21, 891-896 (2003).
100. Reinis M, Indrová M, Mendoza L et al.: HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines. Int. J. Oncol. 25(4), 1165-1170 (2004).
101. Símová J, Bubeník J, Bieblová J, Indrová M, Jandlová T: Immunotherapeutic effcacy of vaccines generated by fusion of dendritic cells and HPV16-associated tumour cells. Folia Biol. (Praha) 5, 19-24 (2005).
102. Li B, Li Q, Zhao QL et al.: Murine dendritic cells modifed with CXCL10 gene and tumour cell lysate mediate potent antitumour immune responses in mice. Scand. J. Immunol. 13, 658-1613 (2007).
103. + T cells against tumors. Cancer Immunol. Immunother. 57, 63-71 (2008).